JAMA Oncology

Association of Changes in Cancer Therapy over 3 Decades with Risk of Subsequent Breast Cancer among Female Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study (CCSS).  8:1765-1774. 2022

Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.  8:1816-1820. 2022

Assessment of Lung Cancer Risk among Smokers for Whom Annual Screening Is Not Recommended.  8:1428-1437. 2022

Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients.  8:1068-1070. 2022

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.  8:1-4. 2022

Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report from the Children's Oncology Group AAML1331 Trial.  8:79-87. 2022

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data from the I-SPY2 Randomized Clinical Trial.  7:1654-1663. 2021

Trends in Late Mortality and Life Expectancy after Allogeneic Blood or Marrow Transplantation over 4 Decades: A Blood or Marrow Transplant Survivor Study Report.  7:1626-1634. 2021

Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection.  7:1064-1065. 2021

Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - Reply.  7:635-636. 2021

Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring during Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report 2021

Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.  6:1355-1362. 2020

Seeing (Hearing Loss) with Fresh Eyes.  6:1335-1337. 2020

Association of Sedentary Behavior with Cancer Mortality in Middle-aged and Older US Adults.  6:1210-1217. 2020

Better Understanding the Importance of Palliative Care for Pediatric Patients.  6:817-818. 2020

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.  6:676-684. 2020

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma.  6:724-734. 2020

Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors before and after Transition of Imatinib to Generic Status.  6:542-546. 2020

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.  6:1759-1765. 2020

Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study.  5:1749-1768. 2019

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma.  5:1141-1149. 2019

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.  5:1066. 2019

Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women with Early-Stage Breast Cancer: A Randomized Clinical Trial.  5:710-714. 2019

Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.  5:195-203. 2019

Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.  4. 2018

Health barriers and patterns of gastric cancer care in rural central American resource-limited settings.  4:1131-1133. 2018

Association between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection.  4:930-937. 2018

Possible underestimation of the provision of palliative care.  4:884-885. 2018

A magnetic resonance imaging–based prediction model for prostate biopsy risk stratification.  4:678-685. 2018

Association of mismatch repair mutation with age at cancer onset in lynch syndrome implications for stratified surveillance strategies.  3:E1-E5. 2017

Hospital-based end-of-life care and costs for older patients with malignant brain tumors.  3:1581-1582. 2017

Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease.  3:1253-1256. 2017

Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525.  3:784-792. 2017

Resource use and medicare costs during lay navigation for geriatric patients with cancer.  3:817-825. 2017

Drawing the Line in Risk-Reducing Gynecologic Surgery in Women with a BRCA Mutation.  2:1409-1411. 2016

Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study.  2:1277-1286. 2016

Effect of low-magnitude, high-frequency mechanical stimulation on BMD among young childhood cancer survivors a randomized clinical trial.  2:908-914. 2016

Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada.  2:463-469. 2016

The Global Burden of Cancer 2013.  1:505-527. 2015

Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: A children's oncology group study.  1:287-295. 2015